Citigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59
Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ: OLMA ) with a Buy and lowers the price target from $62 to $59.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.